Miniaturized flow cytometry-based in vitro primary human lymphocyte micronucleus assay-validation study

Area of Science:

• Toxicology
• Genetics
• Biotechnology

Background:

• In vitro genotoxicity assays often yield low specificity, leading to unnecessary in vivo testing.
• Cellular characteristics, such as p53 deficiency or altered DNA repair, can contribute to false positive results.
• Primary human lymphocytes (HuLy) offer higher specificity for predicting in vivo genotoxic potential.

Purpose of the Study:

• To develop and validate a miniaturized flow cytometry-based micronucleus test (MNT) using primary human T-lymphocytes.
• To improve the efficiency and reduce the tedium of genotoxicity testing.
• To enhance the specificity of in vitro genotoxicity assays.

Main Methods:

• Development of a miniaturized flow cytometry assay for micronucleus frequency (MN) in primary human T-lymphocytes.
• Validation using a diverse set of 30 compounds, including commercially available genotoxicants, non-genotoxicants, and early pharmaceutical compounds.
• Simultaneous verification of cell division and analysis of hypodiploid events within the same sample.

Main Results:

• The miniaturized flow cytometry HuLy MNT demonstrated promising results, being faster and less labor-intensive than traditional microscopic analysis.
• The assay effectively detected genotoxic compounds with high specificity.
• Analysis of hypodiploid events provided insights into the mode of action (clastogenic vs. aneugenic).

Conclusions:

• The miniaturized flow cytometry HuLy MNT is a reliable and efficient method for genotoxicity assessment.
• This assay enhances specificity, potentially reducing the need for extensive in vivo follow-up studies.
• The methodology offers valuable information on the mechanism of genotoxicity, aiding further compound evaluation.